REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Innopharmax Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Innopharmax Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Established in 2005, INNOPHARMAX is a specialty pharmaceutical company actively engaged in the development and commercialization of therapeutic products to address the unmet needs in the areas of infectious, immunology, and oncology.

Headquarters
9F.,No.20,9Fno.22,Lane 478,Rueiguang Rd. Neihu District
Taipei City; Taipei City;

Contact Details: Purchase the Innopharmax Inc. report to view the information.

Website: http://www.innopharmax.com.tw

Basic Information
Total Employees:
Purchase the Innopharmax Inc. report to view the information.
Outstanding Shares:
Purchase the Innopharmax Inc. report to view the information.
Financial Auditors:
Purchase the Innopharmax Inc. report to view the information.
Incorporation Date:
October 27, 2005
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Ownership Details
Purchase this report to view the information.
14.02%
Purchase this report to view the information.
1.51%
Purchase this report to view the information.
0.54%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Seven Star Pharm. Co., Ltd.
22.17%
Company Performance
Financial values in the chart are available after Innopharmax Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-33.14%▼
Total operating revenue
-41.48%▼
Operating profit (EBIT)
-47.31%▼
EBITDA
-28.3%▼
Net Profit (Loss) for the Period
-42.49%▼
Total assets
-12.45%▼
Total equity
-15.82%▼
Operating Profit Margin (ROS)
-86.51%▼
Net Profit Margin
-97.47%▼
Return on Equity (ROE)
-4.01%▼
Quick Ratio
-10.74%▼
Cash Ratio
-3.9%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo